Sfoglia per Autore
Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer
1999 G. Bolis, F. Parazzini, G. Scarfone, A. Villa, M. Amoroso, E. Rabaiotti, A. Polatti, S. Reina, E. Pirletti
Pelvic and Paraortic Lymph Nodal Status in Advanced Ovarian Cancer and Survival
1999 F. Parazzini, G. Valsecchi, G. Bolis, P. Guarnerio, S. Reina, G. Polverino, D. Silvestri
A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin
2000 J.B. Vermorken, A. Kobierska, B. Chevallier, F. Zanaboni, A. Pawinski, G. Bolis
Site of origin of epithelial ovarian cancer: the endometriosis connection
2000 P. Vercellini, G. Scarfone, G. Bolis, G. Stellato, S. Carinelli, P.G. Crosignani
p53 Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian Carcinoma
2000 C. Lavarino, S. Pilotti, M. Oggionni, L. Gatti, P. Perego, G. Bresciani, M. A. Pierotti, G. Scambia, G. Ferrandina, A. Fagotti, C. Mangioni, V. Lucchini, F. Vecchione, G. Bolis, G. Scarfone, F. Zunino
Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer
2001 H.C. Wagenaar, S. Pecorelli , I. Vergote, D. Curran, D.J. Wagener, A. Kobierska, G. Bolis, W.T. Bokkel-Huinink , A.J. Lacave, C. Madronal, M. Forn, C.F. de Oliveira, C. Mangioni, M.A. Nooij, A. Goupil, P. Kerbrat, C.H. Marth, S. Tumolo, M.G. Herben, F. Zanaboni, J.B. Vermorken
Response and Toxicity to Topotecan in Sensitive Ovarian Cancer Cases with Small Residual Disease after First-Line Treatment with Carboplatinum and Paclitaxel
2001 G. Bolis, G. Scarfone, S. Tateo, G. Mangili, A. Villa, F. Parazzini
Role of secondary surgery in relapsed ovarian cancer
2001 F. Parazzini, F. Raspagliesi, P. Guarnerio, G. Bolis
Clinical Evidence for Topotecan-Paclitaxel Non–Cross-Resistance in Ovarian Cancer
2001 M. Gore, W. ten Bokkel Huinink, J. Carmichael, A. Gordon, N. Davidson, R. Coleman, M. Spaczynski, J.F. Héron, G. Bolis, H. Malmström, J. Malfetano, C. Scarabelli, P. Vennin, G. Ross, S.Z. Fields
Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian Cancer
2001 G. Bolis, G. Scarfone, G. Giardina, A. Villa, G. Mangili, M. Melpignano, M. Presti, S. Tateo, M. Franchi, F. Parazzini
Phase II Trial of Topotecan, Carboplatin, and Paclitaxel as Front-Line Therapy in Suboptimal Advanced Epithelial Ovarian Cancer
2001 G. Bolis, G. Scarfone, A. Villa, F. Parazzini
Bleomycin, Methotrexate, and CCNU in Locally Advanced or Recurrent, Inoperable, Squamous-Cell Carcinoma of the Vulva: An EORTC Gynaecological Cancer Cooperative Group Study
2001 H.C. Wagenaar, N. Colombo, I. Vergote, G. Hoctin-Boes, G. Zanetta, S. Pecorelli, A.J. Lacave, Q. Van Hoesel, A. Cervantes, G. Bolis, M. Namer, C. Lhomme´, J.P. Guastalla, M.A. Nooij, A. Poveda, V. Scotto di Palumbo, J. B. Vermorken
A Phase I/II Study of Topotecan in Combination with Carboplatin in Recurrent Epithelial Ovarian Cancer
2001 G. Bolis, G. Scarfone, C. Sciatta, G.P. Polverino, C. Rosa, P. Guarnerio, F. Parazzini
International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma
2003 J.B. Trimbos, M. Parmar, I. Vergote, D. Guthrie, G. Bolis, N. Colombo, J.B. Vermorken, V. Torri, C. Mangioni, S. Pecorelli, A. Lissoni, A.M. Swart
Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer–Adjuvant ChemoTherapy in Ovarian Neoplasm Trial
2003 J.B. Trimbos, I. Vergote, G. Bolis, J.B. Vermorken, C. Mangioni, C. Madronal, M. Franchi, S. Tateo, G. Zanetta, G. Scarfone, L. Giurgea, P. Timmers, C. Coens, S. Pecorelli
Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group
2003 F.H. van Wijk, C. Lhommé, G. Bolis, V. Scotto di Palumbo, S. Tumolo, M. Nooij, C.F. de Oliveira, J.B. Vermorken
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
2003 M.S. Aapro1, F.H. van Wijk, G. Bolis, B. Chevallier, M.E.L. van der Burg, A. Poveda, C. F. de Oliveira, S. Tumolo, V. Scotto di Palumbo, M. Piccart, M. Franchi, F. Zanaboni, A. J. Lacave, R. Fontanelli, G. Favalli, P. Zola, J. P. Guastalla, R. Rosso, C. Marth, M. Nooij, M. Presti, C. Scarabelli, T.A.W. Splinter, E. Ploch, L.V.A. Beex, W. ten Bokkel Huinink, M. Forni, M. Melpignano, P. Blake, P. Kerbrat, C. Mendiola, A. Cervantes, A. Goupil, P.G. Harper, C. Madronal, M. Namer, G. Scarfone, J.E.G.M. Stoot, I. Teodorovic, C. Coens, I. Vergote, J.B. Vermorken
Paclitaxel 175 or 225 mg per Meters Squared With Carboplatin in Advanced Ovarian Cancer: A Randomized Trial
2004 G. Bolis, G. Scarfone, G. Polverino, F. Raspagliesi, S. Tateo, G. Richiardi, M. Melpignano, M. Franchi, G. Mangili, M. Presti, A. Villa, E. Conta, P. Guarnerio, S. Cipriani, F. Parazzini
Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy
2005 G. Polverino, F. Parazzini, G. Stellato, G. Scarfone, S. Cipriani, G. Bolis
Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer : results from a phase II study
2006 G. Bolis, S. Danese, S. Tateo, E. Rabaiotti, G. D'Agostino, C. Merisio, G. Scarfone, G. Polverino, F. Parazzini
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile